BioVentrix has withdrawn the Nasdaq IPO it filed in February, which sought about $17 million under the ticker BVXX. The withdrawal filing says the terms of the offering were never set and no securities were sold.
The company raised a $48.5 million Series A in 2023. Its Revivent system reshapes a dilated left ventricle after a heart attack using titanium anchor implants placed through a less invasive approach. Revivent has carried a CE mark since 2016 and holds an FDA breakthrough device designation.
The pivotal RELIVE trial is randomizing about 135 patients with symptomatic heart failure and left ventricular scarring, with one year of follow-up. The first patient was treated in November 2025 at Saint Luke's Mid America Heart Institute in Kansas City. The trial added sites this month, including one in Tbilisi, Georgia, where two patients went home in five days.
Oura shelved a $2.2 billion Nasdaq IPO in late September and pointed at market uncertainty. Two device listings pulled inside three weeks says more about the window than about either company.